A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Eton Pharmaceuticals, Inc. ETON

Mixed broader-coverage candidate · Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

On FrontierLab's discovery record since 2026-07-28 (3 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-15), not the curated Frontier signal.

⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.

⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)	81.5%
Gross margin	57.9%
Gross profits / assets	0.53
Rule of 40	96.9
Net margin	15.4%
Cash runway (months)	—
PEG	—
Price / sales	15.3

Quality checklist

~ Revenue growth — 81.5% (pass ≥ 20%)
✓ Gross profits / assets — 0.53 (pass ≥ 0.33)
~ Gross margin — 57.9% (pass ≥ 60%)
✓ Cash generation
✗ Share dilution — 21.9%

Fundamentals — snapshot as of 2026-08-15

Stage	Established
Share issuance (YoY)	21.9% · heavy issuance
Moat	—
TAM	—
P/E (trailing)	153
EPS (trailing)	$0.38
Burn multiple	—
Gross-margin trend (pts)	-1.5
Cash / assets	0.23
Net debt / EBITDA	-0.9
Statements as of	Q2 FY2026 · filed 2026-08-13

Momentum context — a snapshot from 2026-08-15, not current

Price at surface	$58.86 (as of 2026-08-15)
52-week range	$14.27 – $59.79
% off 52-wk high	-1.6%
RSI (14)	76
Relative volume	3.7×

Risk flags

Heavy dilution (~22%/yr) — top-decile share issuers have historically underperformed.Parabolic one-day spike (+44%) in the last month — extreme single-day moves tend to mean-revert.Volume 3.7× normal alongside the move — attention-crowded names tend to reverse over the following weeks.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-15 (end-of-day). How grades are computed →